Sanofi loses Lantus patent claims against Mylan
[NEW YORK] US generics drugmaker Mylan NV said on Thursday the US Patent and Trademark Office rejected French pharma company Sanofi's patent infringement claims related to two formulations of its blockbuster insulin drug Lantus.
Sanofi has previously filed patent infringement suits against other rivals, including Merck and Co and Eli Lilly & Co, to block cheaper versions of the diabetes drug from coming to the market.
The company is heavily reliant on Lantus, its leading product with sales of 4.62 billion euros (S$7.2 billion) in 2017.
Sanofi's Paris-listed shares fell 1 per cent. The company declined to comment.
Lantus is a long-acting insulin used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes to control high blood sugar.
Sanofi, which settled with Lilly allowing it to launch Basaglar, an insulin similar to Lantus in 2016, sued Mylan in October 2017.
The case includes some patents covering a disposable injection pen version, Lantus SoloSTAR. That litigation is pending and no trial date has been set, Mylan said.
Mylan's generic versions of Lantus and Lantus SoloSTAR, developed with India's Biocon, are being reviewed by the US Food and Drug Administration.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Sony deal for Paramount would draw added regulatory scrutiny
Lululemon to shutter Washington distribution center, lay off 128 employees
Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece
P&G raises annual core profit forecast on resilient demand, price hikes
Cordlife calls for trading halt after shares sink to all-time low, pending announcement
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom